The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial.
 
Mark Zafereo
Research Funding - Exelixis; Lilly (Inst); Merck (Inst)
Other Relationship - American Academy of Otolaryngology-Head and Neck Surgery; American Thyroid Association; Thyroid International Recommendations Online
(OPTIONAL) Uncompensated Relationships - International Thyroid Oncology Group
 
Rui Wang
No Relationships to Disclose
 
Naifa Busaidy
Honoraria - Eisai; Exelixis; Lilly
Consulting or Advisory Role - Eisai
 
Ramona Dadu
Honoraria - Bayer
Consulting or Advisory Role - Exelixis
Research Funding - AstraZeneca (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)
 
Priyanka Iyer
Research Funding - Bristol Myers Squibb
 
Steven Waguespack
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Camurus
Travel, Accommodations, Expenses - Bayer
 
Li Xu
No Relationships to Disclose
 
Anastasios Maniakas
Research Funding - Jazz Pharmaceuticals (Inst); Thryv Therapeutics Inc (Inst)
 
Victoria Banuchi
No Relationships to Disclose
 
Stephen Lai
Consulting or Advisory Role - Cardinal Health
 
Steven Chinn
No Relationships to Disclose
 
Jessica Geiger
Consulting or Advisory Role - Astellas Pharma; AVEO; EMD Serono
Research Funding - Alkermes (Inst); Genentech/Roche (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Regeneron (Inst)
 
Kathleen Kerrigan
Stock and Other Ownership Interests - bristol myers squibb (I)
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Genentech; Sanofi
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Janssen (Inst); Merck (Inst); Merus NV (Inst)
 
Saad Khan
Consulting or Advisory Role - Eisai; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Kineta
Research Funding - Abbvie (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Formation Biologics (Inst); Genentech (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst)
 
Eric Moore
No Relationships to Disclose
 
Mabel Ryder
No Relationships to Disclose
 
Joseph Scharpf
No Relationships to Disclose
 
Francis Worden
Honoraria - Eisai; Exelixis; Merck Sharp & Dohme; Merus; PDS Biotechnology; Sun Pharma Advanced Research Company
Consulting or Advisory Role - Adlai Nortye; Coherus Biosciences; Coherus Biosciences; Exelixis; Merck; PDS Biotechnology; Sun Pharma Advanced Research Company
Research Funding - Adlai-Nordlyte; Coherus Biosciences; CUE Biopharma (Inst); EpicentRx; Loxo/Lilly (Inst); Merck (Inst); PDS Biotechnology
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Sun Pharma Advanced Research Company
 
Michelle Williams
Speakers' Bureau - Springer
Research Funding - Bayer Health
 
Maria Cabanillas
Honoraria - Boston University; University of Miami
Consulting or Advisory Role - Bayer; Exelixis; Novartis; Thryv
Research Funding - Eisai; Exelixis; Merck; Roche/Genentech